Categories: inc.

27 March 2020 02:00

Yamaha Motor and Tier IV Establish JV for autonomous transportation service - Will help factories combat labor shortages through further automation -

Yamaha Motor Co., Ltd. and Tier IV, Inc. today announced the launch of eve autonomy, Inc., a joint-venture company based in Shizuoka Prefecture, Japan, that will develop an autonomous transportation service to help Yamaha Motor and other companies address chronic labor shortages and growing needs for high-mix low-volume production.
Beginning in April, eve autonomy will begin offering easil

4 July 2019 01:00

Yamaha Motor Invests Further in Autonomous Driving Technology Developer "Tier IV"　- Strengthening Development Capabilities for Low-Speed Autonomous Driving Vehicles -

IWATA, July 4, 2019 - Yamaha Motor Co., Ltd. (Tokyo:7272) today announced its decision to make additional investment in Tier IV, Inc., which is engaged in the development of Autoware autonomous driving OS software. Through this investment, Yamaha Motor aims to strengthen development capabilities and acquire knowledge regarding low-speed autonomous driving technology.
Through this additional

24 May 2019 02:00

Yamaha Motor Enhances Philippine based Motorcycle Production　- Responding to Future Market Expansion -

IWATA, May 24, 2019—Yamaha Motor Co., Ltd. (Tokyo: 7272) announced today plans to increase the production capacity of motorcycles at Yamaha Motor Philippines, Inc. (YMPH) who manufactures and sells motorcycles based within the Lima Technology Center in the Province of Batangas.
Under this plan, a new plant will be built on the same site, with the annual production capacity to be raised from

31 August 2018 02:00

Yamaha Motor Invests in Bioventure Firm Evec, Inc.　- Promoting Strategic Partnering in the Biomedical Field -

IWATA, August 31, 2018 - Yamaha Motor Co., Ltd. announced today that, aiming to acquire a deeper level of knowledge and upgrade product development capabilities in the ever-growing biomedical research field, the Company has decided to invest in bioventure firm Evec, Inc.
Evec has strengths in the manufacturing and sale of “SEED antibodies,” which are essential in drug discovery, testing